Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
about
A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress.Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.
P2860
Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@ast
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@en
type
label
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@ast
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@en
prefLabel
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@ast
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@en
P2093
P2860
P1433
P1476
Topotecan weekly bolus chemoth ...... varian and peritoneal cancers.
@en
P2093
Adnan Munkarah
Christopher Bryant
Daryn Smith
Lance K Heilbrun
Robert Morris
Ronald D Alvarez
Stephen Andrews
Veronica Schimp
P2860
P304
P356
10.1016/J.YGYNO.2008.02.028
P407
P50
P577
2008-04-14T00:00:00Z